Hengrui Presents Oncology Research Data at ESMO 2026 Congress
Chinese pharmaceutical firm Hengrui detailed 64 research projects at the European Society for Medical Oncology congress in Madrid, focusing on new approaches to cancer treatment.
Shanghai-based Hengrui showcased 64 research papers during the 2026 European Society for Medical Oncology (ESMO) congress in Madrid. The presentation focused on the company's oncology pipeline and its progress in international clinical trials.
The data shared by Hengrui highlights its ongoing development of novel therapeutics aimed at various cancer types. By utilizing the ESMO platform, the company is attempting to increase its presence in Western medical markets, moving beyond its traditional stronghold in the domestic Chinese market.
Industry analysts note that Hengrui's effort to integrate into the global oncology sector relies on successful phase trials and regulatory approvals in Europe and North America. The volume of research presented suggests a shift toward high-frequency international data disclosure to compete with multinational pharmaceutical companies.
The congress concludes with Hengrui emphasizing its current clinical pipeline, as the firm seeks to establish broader partnerships for its oncology drug candidates.